Recent phase II trials demonstrated a positive trend toward increased clinical response to JAK1 inhibition compared with placebo (brepocitinib, 51.9% vs. 33.3%; povorcitinib, 48.1% vs. 28.8%: and upadacitinib, 38.3% vs. 23.8%) ( 32 , 33 , 34 ).
← all excerpts
Hidradenitis suppurativa: key insights into treatment success and failure.
1
—
—